Our Parent Company
Founded in 2008 as a subsidiary of Stemedica Cell Technologies Inc., Stemedica International’s strong relationship with the parent company includes an exclusive, worldwide Stemedica license for the exploration of therapeutic indications for degenerative conditions, such as Alzheimer’s disease and dementia. Stemedica focuses on stem cell manufacturing technology, scale-up manufacturing and other related activities, while Stemedica International implements stem cell therapies to explore neurodegenerative conditions such as Alzheimer’s disease, vascular dementia and related disorders.
Incorporated in 2005, Stemedica Cell Technologies Inc. has become a global biopharmaceutical company led by prominent scientists, leading clinicians, experienced investors and seasoned medical, biotechnology and pharmaceutical executives. Its mission is to develop and manufacture best-in-class, ischemic-tolerant, allogeneic stem cells that support pre-clinical and clinical studies conducted by approved research institutions and accredited hospitals.
Stemedica’s stem cell manufacturing capacity is among the finest in the world. The company operates a U.S. FDA-compliant cGMP (Current Good Manufacturing Practices) facility in San Diego, California, that is licensed by the Food and Drug Branch of the State of California Department of Health and Human Services. It also has manufacturing facilities and master banks in Lausanne, Switzerland.